Medlive Technology Co., Ltd.
Medlive Technology Co., Ltd. (HKSE: 2192) is trading at HK$6.71, about ₹82 at today's HKD/INR rate, as of 30 Sep 2026, 2:56 AM ET, down 0.15% today. Indian residents can buy Medlive Technology from India on Paasa under the RBI's Liberalised Remittance Scheme.
Quote
Today's low
HK$6.64
Today's high
HK$6.75
52 week low
HK$6.31
52 week high
HK$15.01
2192 opened at HK$6.70, closed previously at HK$6.72, and has traded between HK$6.31 and HK$15.01 over the past 52 weeks.
About
Medlive Technology Co., Ltd., along with its affiliated entities, manages a digital platform tailored for medical professionals, serving both the Chinese mainland and international markets. Through its comprehensive platform, the company delivers a precision marketing and corporate solution encompassing a wide array of services. These include project oversight, clinical supervision, handling of clinical data, biostatistical analysis, drafting of study protocols, medical supervision, patient enrollment, and system support. Furthermore, it offers digital market intelligence, electronic data collection, real-world evidence generation, and the development of application software. Medlive also provides a medical knowledge solution focused on continuing medical education and tools for clinical decision-making, which involves licensing specialized software to physicians and other registered users, including various healthcare practitioners and pharmaceutical corporations. An intelligent patient management solution is another core offering, delivering chronic disease management services that cover online consultations, prescription fulfillment, and patient care facilitated by an Internet hospital. Additionally, it provides condition-specific patient education, involving the creation of content, development of specialized software, and associated support services. Originally established in 1996 as Kingyee Co., Limited, the enterprise adopted the name Medlive Technology Co., Ltd. in 2021. Its corporate headquarters are located in Beijing, China.
Key statistics
Avg. volume
1.37M
Market cap
HK$4.97B
P/E Ratio
12.46
Price-to-sales ratio
6.57
Enterprise value
CN¥3.86B
Free cash flow yield
1.90%
Debt-to-equity ratio
0.00
Return on equity
6.87%
ROIC
1.79%
Beta
0.44
Dividend yield
4.68%
Last dividend
HK$0.29
Financial overview
Revenue
CN¥642.15M
Earnings per share
CN¥0.45
Free cash flow
CN¥121.70M
Net profit margin
52.77%
Gross margin
61.31%
EBITDA
CN¥174.99M
Revenue growth
14.99%
Similar securities
This is not an investment recommendation
How to buy Medlive Technology from India
Indian residents can buy Medlive Technology shares through Paasa in four steps. Funds leave India under the RBI's Liberalised Remittance Scheme and the shares are held in your own name with Interactive Brokers.
Open a Paasa account
Complete digital KYC with your PAN, Aadhaar and address proof. Your brokerage account is opened in your own name with Interactive Brokers.
Add funds under LRS
Transfer INR from your Indian bank account. Your bank reports the remittance under the RBI's Liberalised Remittance Scheme and converts it to US dollars and then to HKD.
Search for Medlive Technology and place an order
Find Medlive Technology by name or by its ticker, 2192, and choose an order type. Many Hong Kong listings trade in board lots, so the smallest order is one lot rather than one share. Medlive Technology trades 7:00 am – 1:30 pm IST; orders can only execute during that window.
Track holdings and download tax reports
Follow your Medlive Technology position in HKD and INR, and use Paasa's capital-gains and dividend statements when you file your Indian return.
Read the full guide: how to invest in Medlive Technology from India
Trading and taxes when buying Medlive Technology from India
Trading and limits
- Trading hours
- 9:30 am – 4:00 pm HKT
- LRS limit
- $250,000Per financial year, under the RBI's Liberalised Remittance Scheme.
Tax for Indian residents
- TCS on remittance
- 20%Collected by your bank on LRS remittances above ₹10 lakh in a financial year. The TCS is adjustable against your income-tax liability.Adjusting TCS against your tax
- Capital gains in India
- 12.5% or slab rateGains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate.Capital gains explained
- Dividends
- Slab rateDividends are taxed at your slab rate in India. Medlive Technology’s current yield is 4.68%.Dividend tax explained
Custody. Shares are held in your own name at Interactive Brokers, segregated from Paasa's own assets.
FAQs
Can Indian residents buy Medlive Technology stock?
Yes. Medlive Technology (2192) has been listed on the Hong Kong Stock Exchange since 2021, in the Medical - Healthcare Information Services industry, and Indian residents can buy it through Paasa. You fund the account from your Indian bank under the RBI's Liberalised Remittance Scheme and the money is converted to US dollars and then to HKD. Shares are held in your own name at Interactive Brokers, segregated from Paasa's own assets.
How much does one Medlive Technology share cost in rupees?
One Medlive Technology share is HK$6.71 — about ₹82 at an HKD/INR rate of 12.24 on 29 Sep 2026. Both the Medlive Technology price and the rupee rate move during the day, so the rupee cost changes with them.
What are the LRS and TCS rules for buying Medlive Technology from India?
Remit up to $250,000 per financial year under the RBI's Liberalised Remittance Scheme (LRS). Banks collect 20% tax at source on LRS remittances above ₹10 lakh in a financial year; the TCS is adjustable against your income-tax liability. FX and the LRS declaration are handled by your bank when you fund your account.
What is the minimum I can buy of Medlive Technology?
Many Hong Kong listings trade in board lots, so the smallest order is one lot rather than one share.
How are gains on Medlive Technology shares taxed in India?
Hong Kong generally does not levy capital gains tax on non-resident individual investors for HKEX-listed stocks, so the tax is an India-side one. Gains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. The gain is computed in rupees using the HKD/INR rate on the purchase and the sale date, so the rupee move counts alongside the Medlive Technology price. Paasa issues a capital-gains statement for your return.
Does Medlive Technology pay a dividend, and how is it taxed in India?
Yes. Medlive Technology pays a dividend and the current yield is 4.68%; the last declared dividend was HK$0.29 per share, about ₹3.56. Dividends are taxed at your slab rate in India. Paasa's dividend report lists the gross dividend and any tax withheld for each payment.
When can I trade Medlive Technology from India?
The Hong Kong Stock Exchange trades 7:00 am – 1:30 pm IST in Indian time. It also halts for lunch, 9:30 am – 10:30 am IST. Orders can only execute during that window.
Is Medlive Technology a Hong Kong SAR China company, and does that change how it is taxed?
Medlive Technology trades on the Hong Kong Stock Exchange in HKD, but the company is domiciled in China. Medlive Technology trades as an ordinary share listed directly in Hong Kong, not a depositary receipt. Your India-side capital-gains treatment is the same either way.
Do I have to declare Medlive Technology shares in my Indian tax return?
Yes. Foreign shares held on 31 March must be reported in Schedule FA of your Indian income-tax return. Paasa gives you a Schedule FA-ready statement listing your Medlive Technology holding, its cost and its closing value.
How do I sell Medlive Technology and bring the money back to India?
You sell during market hours (7:00 am – 1:30 pm IST) and the proceeds settle in HKD in your Paasa account. From there you can hold the balance, reinvest, or repatriate. Funds can be withdrawn in any currency to any bank account in your own name. Whether the sale is short- or long-term is decided by the 24-month holding period.